Cargando…

Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer

BACKGROUND: The sigma-2 receptor has been validated as a biomarker for proliferating tumours. Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria into the cytosol, leading to apoptosis. In this study, we investigated a sigma-2 ligand as a tumour-targeting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, C, Vangveravong, S, McDunn, J E, Hawkins, W G, Mach, R H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817331/ https://www.ncbi.nlm.nih.gov/pubmed/24104966 http://dx.doi.org/10.1038/bjc.2013.593

Ejemplares similares

Sigma-2 ligands induce tumour cell death by multiple signalling pathways
por: Zeng, C, et al.
Publicado: (2012)

Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer
por: Garg, Gunjal, et al.
Publicado: (2014)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10
por: Raulf, N, et al.
Publicado: (2014)

Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma
por: Kashiwagi, Hiroyuki, et al.
Publicado: (2009)

The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer
por: Hashim, Yassar M., et al.
Publicado: (2017)

The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer
por: Binder, Pratibha S., et al.
Publicado: (2022)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin
por: García-Santos, G, et al.
Publicado: (2012)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands
por: Almazán-Moga, A, et al.
Publicado: (2017)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
por: Hermida-Prado, Francisco, et al.
Publicado: (2023)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer
por: Hornick, John R, et al.
Publicado: (2012)

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression
por: Dubois, L, et al.
Publicado: (2007)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
por: Duran, George E, et al.
Publicado: (2017)

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine
por: Hornick, John R, et al.
Publicado: (2010)

Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases
por: Kim, S H, et al.
Publicado: (2008)

Future Therapeutic Directions for Smac-Mimetics
por: Morrish, Emma, et al.
Publicado: (2020)

Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways
por: Miles, Mark A., et al.
Publicado: (2018)

Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer
por: Noonan, Anne M., et al.
Publicado: (2020)

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
por: Chen, H, et al.
Publicado: (2009)

Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours
por: White, D E, et al.
Publicado: (2010)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy
por: Kashiwagi, Hiroyuki, et al.
Publicado: (2007)

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
por: Köbel, M, et al.
Publicado: (2014)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
por: Zhong, W, et al.
Publicado: (2009)

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
por: PosthumaDeBoer, J, et al.
Publicado: (2013)

New light on Smac mimetics and breast cancer
por: Cornmark, L, et al.
Publicado: (2016)

Hyperosmotic stress enhances cytotoxicity of SMAC mimetics
por: Bittner, Sebastian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vht9v5gitvfpl868k3crdv07h2